News Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-29 pm EDT			5-day change	1st Jan Change
103,100 ^KRW	-3.19%		-4.89%	-11.73%

May. 14	Daewoong Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daewoong Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Daewoong Pharmaceutical : Reports Q1 2024 Financial Results	Apr. 29	PU
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	Apr. 24	MT
AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	Apr. 11	CI
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	Mar. 18	CI
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia	Feb. 15	MT
Daewoong Pharmaceutical : and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S.	Dec. 11	PU
Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., Ltd. Announces Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S	Dec. 10	CI
Daewoong Pharmaceutical : Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin	Dec. 05	PU
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA	Nov. 27	AQ
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy	Nov. 06	CI
P.T. Selatox Bio Pharma announced that it expects to receive IDR 200 billion in funding from Daewoong Pharmaceutical Co., Ltd	23-10-26	CI
Daewoong Pharmaceutical : announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030	23-10-25	PU
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market	23-10-19	AQ
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema	23-09-25	CI
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia	23-08-30	MT
Hyphens Pharma International Limited Announces Successful Registration in Malaysia	23-08-30	CI
Daewoong Pharmaceutical : Initiates Global Export of 'Novel Drug'...Launches 'Fexuprazan' in the Philippines	23-08-17	PU
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

Summary

Filters